Canadian Cancer Trials Group Bulletins

General


SC.23 Results Among CCS 2015 Top 10 Research Impact Stories

Results of Canadian Cancer Trials Group SC.23 show that dexamethasone lowers the rate of pain flare in cancer patients with bone metastases undergoing radiation therapy for symptom control and was included among the Canadian Cancer Society's Top 10 Research Impact Stories of 2015.

Here is a link to all 10 Research Impact Stories ... http://www.cancer.ca/en/about-us/for-media/media-releases/national/2016/top-10-research-impact-stories-of-2015/?region=on.

These results were first presented by the SC.23 trial co-chair, Dr. Edward Chow from Sunnybrook Health Sciences Centre in Toronto, at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio on October 18, 2015. Dr. Alysa Fairchild from the Cross Cancer Institute in Edmonton, SC.23 co-chair, then presented these same results the next day as part of ASTRO's press program.

You can view Dr. Fairchild's slides and the SC.23 press release by using these links:

https://www.astro.org/News-and-Media/Media-Resources/Press-Kits/Annual-Meeting-2015/briefings2015_3.aspx

https://www.astro.org/News-and-Media/News-Releases/2015/Fairchild_AM15.aspx

These results were also published in The Lancet Oncology ... http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00199-0/abstract.

Congratulations to the SC.23 trial team on this exciting accomplishment.

Thank you to all participating centres, staff and patients for your participation in this study.
Congratulations to Drs. Chow and Fairchild, and thanks to all participating centres, staff and patients for their participation in this study.